# Paw Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paw-therapeutics

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Latest round: Angel (May 18, 2026)
- Investors on record: 1

## About

Based in Shenzhen, China and founded in 2025, PAW Therapeutics Development (Shenzhen) Limited, dba Paw Therapeutics, is a company engaged in the research and development of anti-aging drugs, utilizing AI (artificial intelligence) platforms. The company was established by a group of professors, PhDs, and Graduates from the University of Oxford and the University of California, Berkeley led by Simiao Zhao who holds an undergraduate degree in Computer Science and AI from the University of Edinburgh and master's and doctoral degrees from Oxford. 

In May 2026, Paw Therapeutics closed a round of angel funding led by Monolith Management.

Paw Therapeutics focuses on developing anti-aging drugs for both pets and human, aiming to apply real-world data accumulated from clinical trials on pets to the development of human anti-aging drug pipelines. The company uses AI-driven models and platforms with cross-species biological data. for target discovery and antibody drug optimization. 

The company generates revenue from developing anti-aging drugs.

## Funding rounds

- Angel, May 18, 2026 — Monolith Management

## Investors

- Monolith Management (https://capitalatlas.ai/funds/monolith-management) — Angel